Methylenedioxybutylamphetamine

Methylenedioxybutylamphetamine (MDBA) is a psychoactive drug and a member of the phenethylamine and amphetamine chemical classes. It is known for its entactogenic effects, similar to those of MDMA, but with a longer duration of action.

History

MDBA was first synthesized in the 1960s by Alexander Shulgin, a renowned chemist and psychopharmacologist. It was later included in Shulgin's book PiHKAL (Phenethylamines I Have Known And Loved), where it was described as a potent entactogen with effects lasting up to 12 hours.

Pharmacology

MDBA acts as a serotonin-norepinephrine-dopamine releasing agent (SNDRA). It increases the levels of these neurotransmitters in the brain by promoting their release from neurons and inhibiting their reuptake. This results in increased neuronal activity and stimulation of the central nervous system.

Effects

The effects of MDBA can vary greatly depending on the dose, the individual's physiology, and the environment in which it is taken. Common effects include feelings of euphoria, increased sociability, heightened sensory perception, and increased energy. However, it can also cause negative effects such as anxiety, paranoia, and potentially dangerous increases in heart rate and blood pressure.

Legal Status

In many countries, including the United States, MDBA is classified as a Schedule I drug under the Controlled Substances Act. This means it is illegal to manufacture, distribute, or possess without a license or prescription.

Health Risks

Like other amphetamines, MDBA can be harmful or potentially fatal if misused. Risks include cardiovascular disease, neurotoxicity, and psychological addiction. It is strongly advised that individuals with a history of mental health issues, particularly mood disorders such as depression or bipolar disorder, avoid use due to the potential for exacerbating these conditions.

See Also

• MDMA
• Methylenedioxyamphetamine
• Phenethylamine
• Amphetamine

• 
  Methylenedioxybutylamphetamine structure